Table 3 Monitoring TP53 mutations over time

From: Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status

Sample ID Retrospective (R) /prospective (P) analysis First available sample: time from dg (y) Study enrollment: time from dg (years) Last available sample: time from dg (years) Total follow-up (years) MPN therapy before study enrollment Therapy after study enrollment Mutation 0.1% in dg sample The development of most abundant mutation (%) a Mutation development during follow-up
186A R 0.0 15.0 15.0 15.0 IFN HUb yes 0.4-8.3-NA Increase
MP15 P/R 0.2 7.0 11.9 11.5 HU, IFN IFN no 0-0.8-2.1-2.6-3.8-4.4-10.7-11.3-11.2(W)13.8(G)  
MP10 P/R 0.0 6.4 9.8 9.8 HU HU no 0-10.1-85.5  
JAK1716 P/R 6.0 9.3 16.2 10.2 IFN IFN→HU NA 0-0.1-0.1-0.2-0.7-2.2-2-2.2  
MP326 P/R 0.0 6.7 9.1 9.1 HU HU no 0-0.6-0.5-0.5  
MP96 P/R 0.0 5.4 8.8 8.8 HU HU no 0-0.5-0.6  
MP168 P/R 2.4 7.1 10.5 8.1 HU HU NA 0.1-1-0.5-0.6  
MP319 P/R 0.0 5.2 7.5 7.5 HU, ANA HU, ANA yes 0.1-0.4-0.4-0.8  
MP369 P 0.0 0.0 7.0 7.0 nonec HU NA NA-0.13-1.4  
65A P 13.2 13.2 19.6 6.5 IFN, ANA IFN, ANA NA NA-1.7-5.4  
MP327 P/R 4.9 10.4 11.2 6.3 HU HU NA 0-0.1-0.5-0.5  
JAK22 P 0.0 0.0 5.0 5.0 nonec HU yes NA-2.0-46.1  
MP273 P 9.3 9.3 12.0 2.8 HU HU NA NA-0.3/0-0.3/1.7  
MP317 P 5.5 5.5 6.0 0.5 HU HU NA NA-0.8-1.9  
MP289 P/R 15.2 22.1 24.6 9.3 HU, IFN none NA 0.2/1.4-3.3/0.7-4.4/0.4-6.3/0.6-3.5/0.4d Increase/decrease
MP68 P/R 0.0 4.8 8.3 8.3 HU, ANA HU→none no 0-6.9-8.8-10.7-11.7-16.9-9.6-2.7  
MP315 P/R 4.6 9.1 11.5 6.9 IFN IFN NA 0.2-0.8-0.4-0.2  
MP230 P 8.0 8.0 9.2 1.2 HU HU NA NA-0.5-2.3-1.3  
MP189 P/R 6.9 11.5 14.6 7.7 ANA HU, ANA NA 3.9-2.8-2.5 Stable
MP155 P/R 5.7 10.2 13.0 7.3 ANA ANA NA 0.4-0.2-0.2  
MP229 P 9.4 9.4 12.4 3.0 HU HU, ANA NA NA-1-0.5-0.6  
MP302 P 19.3 19.3 21.7 2.4 busulfan→HU HU NA NA-0.4-0.4-0.7  
MP329 P 13.5 13.5 15.7 2.2 HU HU, ANA NA NA-2.6-1.9-3.1/3.0  
MP324 P 21.2 21.2 22.0 0.7 HU HU NA NA-0.3-0.4  
221A P/R 0.0 15.0 24.6 24.6 IFN IFN yes 10.2/ND-2.2/0.6-0.7/2.0d Decrease
MP2 P/R 12.1 16.3 21.7 9.6 HU, IFN, ANA HU, ANA NA 11.5-10.6-11.6-2.9-2.2-1.9-2.1  
MP63 P/R 1.5 6.6 10.0 8.5 HU HU NA 0-0.2/0.1-0.1/0.2-0/0d  
MP160 P/R 1.2 5.1 7.1 5.8 HU HU NA 0.5-0.2-0  
MP307 P 8.6 8.6 10.2 1.6 HU HU NA 0.2-0  
MP314 P/R 14.8 19.4 21.9 7.1 busulfan→HU HU NA 3.3/0.2-1.3/0.4-0.6/0.9-0.2/0.2d  
MP345 P/R 0.0 4.2 6.3 6.3 HU HU yes 0.1-1.1-0.9-0.5-0.6  
  1. Abbreviations: G, granulocytes; NA, not available; W, leukocytes.
  2. Mutations with highest VAF are shown. "Study enrollment" describes the sampling from which the mutation was identified. For over-time monitoring and validation of previously identified mutation, cut-off 0.1% was applied (minimal coverage per base 10000). VAF bellow 0.1% considered as a background (0%). Development was cathegorised as follows: increase—VAF twofold increase between first and last sample or no mutation at diagnosis; decrease—VAF decrease in VAF to half between first and last sample or no mutation at last sampling; increase/decrease—increase followed by decrease; stable—other. y, years; NA, not available; G, granulocytes; W, leukocytes.
  3. aResult from study enrollment is highlighted.
  4. bSamples not available.
  5. cMutation identified at diagnosis.
  6. dTwo mutations with the highest VAFs in distinct samplings.